Bortezomib 3.5 Mg Injection 3.5 mg/vial Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 3.5 mg/vial
Reference Brands: Velcade (USA/EU), Bortenat (India)
Category: Oncology Cancer Care
Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It works by blocking proteasomes, the enzyme complexes responsible for breaking down proteins in cells, which leads to cancer cell death. Marketed under the brand name Velcade, it is available as a 3.5 mg/vial powder for injection for intravenous or subcutaneous use. It is an essential drug in modern cancer chemotherapy regimens.
Product Description:
Bortezomib is an important anticancer medicine widely used in the treatment of certain blood-related cancers. It belongs to a class of drugs known as proteasome inhibitors and plays a key role in modern oncology therapy. Bortezomib has been approved for use in the initial treatment of multiple myeloma, often in combination with other medicines such as cyclophosphamide and dexamethasone. It is also used in patients who previously responded to treatment and later experienced a relapse after completing prior therapy.
In addition to multiple myeloma, Bortezomib is approved for the treatment of mantle cell lymphoma in patients who have received at least one prior line of therapy. The medicine works by blocking proteasomes, which are responsible for breaking down proteins inside cells. By inhibiting this process, Bortezomib helps disrupt cancer cell growth and can lead to the death of malignant cells.
Due to its proven clinical effectiveness and established role in cancer treatment protocols, Bortezomib is widely used in oncology centers around the world. It is manufactured by several global pharmaceutical companies and is available in different regulated markets, supporting the treatment of patients with complex hematologic malignancies.
Bortezomib 3.5 Mg Injection — third party manufacturing & bulk supply
Bortezomib 3.5 Mg Injection 3.5 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Bortezomib 3.5 Mg Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Bortezomib 3.5 Mg Injection →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Bortezomib is used for the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes in cancer cells, which leads to the accumulation of proteins inside the cells and ultimately helps slow down or stop the growth of cancer cells.
Bortezomib is a synthetic boronic acid–based compound developed through pharmaceutical research. It belongs to a class of medicines known as proteasome inhibitors that target specific cellular processes involved in cancer cell survival.
Common trade names include Velcade, Bortenat, Bortecad, Borviz, and other regional brands available in global markets.
Bortezomib products are manufactured by companies such as Takeda Pharmaceutical Company and Johnson & Johnson for the original brand Velcade, along with several generic manufacturers in India, Europe, and Latin America.
The generic name is Bortezomib.
Well-known brand names include Velcade (US/EU), Bortenat (India), Bortecad (India), Borviz (India), and several other generic brands available in Europe and Latin American markets.
Bortezomib is manufactured in regulated pharmaceutical facilities in countries such as the United States, India, and several European countries under strict oncology drug manufacturing and quality standards.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
